S&P 500 7,490 +1.05% Nasdaq 25,374 +1.59% Dow Jones 52,485 +1.04% FTSE 100 10,868 +1.23% DAX 25,629 +2.11% Nikkei 225 64,362 -0.88% Hang Seng 25,884 +3.69% WTI Crude 84.67 +6.83% Gold 4,107 +1.75% US 10-Year Treasury Yield 4.745 +2.24% S&P 500 7,490 +1.05% Nasdaq 25,374 +1.59% Dow Jones 52,485 +1.04% FTSE 100 10,868 +1.23% DAX 25,629 +2.11% Nikkei 225 64,362 -0.88% Hang Seng 25,884 +3.69% WTI Crude 84.67 +6.83% Gold 4,107 +1.75% US 10-Year Treasury Yield 4.745 +2.24%

LATEST

Iran says talks with Oman on new Strait of Hormuz shipping route nearing conclusion●IonQ vs. Rigetti: Which Quantum Computing Stock Is a Better Buy in 2026?●Saylor hints at Strategy bitcoin buy after five-week pause as STRC rate stays at 12%: ‘Bitcoin Drive engaged’●Bulgaria's foreign policy balancing act raises concerns over European unity●At 59, She’s Never Had a 401(k). Washington Is About to Auto-Enroll Her in an IRA, and One Choice Decides Whether It Taxes Her Social Security.●A Stock Split Changes Nothing About the Stock's Long-Term Prospects. So Why Does Monster Beverage's Aug. 11 Split Matter?●Got $1,000? Taiwan Semiconductor Manufacturing's $100 Billion Arizona Investment Makes It a Must-Own Stock●3 Quantum Computing Stocks a Top Analyst Says Can Soar●Iran says talks with Oman on new Strait of Hormuz shipping route nearing conclusion●IonQ vs. Rigetti: Which Quantum Computing Stock Is a Better Buy in 2026?●Saylor hints at Strategy bitcoin buy after five-week pause as STRC rate stays at 12%: ‘Bitcoin Drive engaged’●Bulgaria's foreign policy balancing act raises concerns over European unity●At 59, She’s Never Had a 401(k). Washington Is About to Auto-Enroll Her in an IRA, and One Choice Decides Whether It Taxes Her Social Security.●A Stock Split Changes Nothing About the Stock's Long-Term Prospects. So Why Does Monster Beverage's Aug. 11 Split Matter?●Got $1,000? Taiwan Semiconductor Manufacturing's $100 Billion Arizona Investment Makes It a Must-Own Stock●3 Quantum Computing Stocks a Top Analyst Says Can Soar●

Markets

Novo Nordisk shares in hot water after disappointing trial

TST (Full) - (Official Feed) · 1h ago

Novo Nordisk shares in hot water after disappointing trial

Investors who had hopes that Novo Nordisk (NVO) could succeed outside of weight-loss drugs were disappointed on Friday, July 31. The Danish drugmaker said its experimental heart drug Ziltivekimab failed the main goal of a large late-stage trial, and the stock fell fast. Novo has spent 2026 trying ...

Read the full story at TST (Full) - (Official Feed) →

More Markets

Why Morgan Stanley won’t call Rivian a buy despite upgrade

TST (Full) - (Official Feed) · 2h ago

Defunct iconic tire brand files Chapter 11 bankruptcy to dissolve

TST (Full) - (Official Feed) · 2h ago

Big Tech’s $2 trillion AI shakeout just changed everything

TST (Full) - (Official Feed) · 3h ago

Taco Bell outbreak deals blow to parent company's finances

TST (Full) - (Official Feed) · 3h ago